Cargando…
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
AIMS: To confirm the reno‐protective effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors on the onset and progression of chronic kidney disease (CKD) in routine clinical practice. MATERIALS AND METHODS: We conducted a retrospective coh...
Autores principales: | Idris, Iskandar, Zhang, Ruiqi, Mamza, Jil B., Ford, Mike, Morris, Tamsin, Banerjee, Amitava, Khunti, Kamlesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795968/ https://www.ncbi.nlm.nih.gov/pubmed/35676798 http://dx.doi.org/10.1111/dom.14799 |
Ejemplares similares
-
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care
por: Idris, Iskandar, et al.
Publicado: (2021) -
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020) -
Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019) -
The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015) -
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)